Join Growin Stock Community!

欣耀6634.TW Overview

TW StockBiotech. & Medical
(No presentation for 6634)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

欣耀（6634）Overall Performance

欣耀（6634）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

欣耀（6634） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

欣耀（6634）Key Information

欣耀（6634）Profile

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.

欣耀（6634）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7813.97
PB Ratio
2.24
Price-to-FCF
235.24
METRIC
VALUE
vs. INDUSTRY
Gross Margin
88.41%
Net Margin
-94847.87%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7813.97
PB Ratio
2.24
Price-to-FCF
235.24
Gross Margin
88.41%
Net Margin
-94847.87%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6634

欣耀

35.95D

-1.39%

(-0.01)

  • When is 6634's latest earnings report released?

    The most recent financial report for 欣耀 (6634) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6634's short-term business performance and financial health. For the latest updates on 6634's earnings releases, visit this page regularly.

  • How much cash does 6634 have?

    At the end of the period, 欣耀 (6634) held Total Cash and Cash Equivalents of 31.66M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is 6634's EPS continuing to grow?

    According to the past four quarterly reports, 欣耀 (6634)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.92. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6634?

    欣耀 (6634)'s Free Cash Flow (FCF) for the period is -5.13M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 29.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.